The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1559
ISSUE1559
November 5, 2018
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
November 5, 2018 (Issue: 1559)
The FDA has approved two subcutaneously
injected calcitonin gene-related peptide (CGRP)
antagonists, fremanezumab-vfrm (Ajovy – Teva) and
galcanezumab-gnlm (Emgality – Lilly), for migraine
prevention in adults. Fremanezumab and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.